Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Shore on the Tolerability of Darolutamide in Nonmetastatic CRPC

July 20th 2020

Neal D. Shore, MD, FACS, discusses the safety and tolerability benefits of darolutamide in men with nonmetastatic castration resistant prostate cancer.

Dr. Gafita on the Rationale to Evaluate 177Lu-PSMA-617 in mCRPC

July 17th 2020

Andrei Gafita, MD, discusses the rationale to evaluate lutetium-177 PSMA-617 in metastatic castration-resistant prostate cancer.

Sternberg Showcases Promising PROSPER Data With Enzalutamide in Nonmetastatic CRPC

July 16th 2020

Cora N. Sternberg, MD, discusses the data seen with enzalutamide in nonmetastatic castration-resistant prostate cancer, the updated survival results from the phase 3 PROSPER trial, and how she chooses among the agents available in the space.

Niraparib/Radium-223 Combo Shows Tolerability in Early-Phase CRPC Trial

July 16th 2020

William K. Kelly, DO, discusses the early data seen with radium-223 plus niraparib and the next steps for this regimen in castration-resistant prostate cancer.

Patient Outcomes Support Cabazitaxel Over Standard in mCRPC

July 14th 2020

Findings from a preplanned analysis of the phase 4 CARD study demonstrated superior patient-reported outcomes with cabazitaxel in men with castration-resistant prostate cancer who received prior docetaxel and androgen receptor targeted therapy versus alternative AR-targeted treatment options.

Dr. Rana on Using Age at Diagnosis to Guide the Utility of Genetic Testing in Prostate Cancer

July 14th 2020

Huma Q. Rana, MD, MPH, discusses the use of age at diagnosis to guide the utility of genetic testing in men with prostate cancer.

Dr. Stenzl on the Safety Profile of Enzalutamide/ADT in mHSPC

July 13th 2020

Arnulf Stenzl, MD, discusses the safety profile of enzalutamide in combination with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.

Shore Shares Promise of Relugolix for T-Suppression in Advanced Prostate Cancer

July 13th 2020

Neal D. Shore, MD, FACS, discusses the pivotal HERO trial, the promising safety data observed with relugolix, and the next steps for the agent in advanced prostate cancer.

Dr. Sartor on the Significance of the REASSURE Trial in mCRPC

July 10th 2020

Oliver Sartor, MD, discusses the significance of the REASSURE trial in patients with metastatic castration-resistant prostate cancer.

Experts Focus on 6 Life-Prolonging Treatments for mCRPC

July 9th 2020

During a recent OncLive Peer Exchange, a panel of experts in advanced prostate cancer provided their insights on how best to employ 6 therapies that are enabling men with mCRPC to live longer.

Dr. Morris on the Design of the Phase 3 CONDOR Trials in Recurrent Prostate Cancer

July 9th 2020

Michael J. Morris, MD, discusses the design of the phase 3 CONDOR trial in men with biochemically recurrent prostate cancer.

Dr. Katz on Redefining Risk Stratification in Prostate Cancer

July 9th 2020

Aaron E. Katz, MD, FACS, discusses redefining risk stratification for men with prostate cancer.

Emerging Therapies for Advanced Prostate Cancer

July 9th 2020

Radium-223 in Metastatic CRPC

July 9th 2020

Genetic Testing in Metastatic CRPC

July 9th 2020

Impact of Clinical Data on the Treatment of mCRPC

July 9th 2020

The CARD and PROfound Trials for Metastatic CRPC

July 9th 2020

Differences Between AR-Targeted Therapy in Prostate Cancer

July 9th 2020

Overall Survival Data Presented at ASCO 2020 for nmCRPC

July 9th 2020

FDA Approved Agents for Non-Metastatic CRPC

July 9th 2020